1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
Spinal Muscular Atrophy Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Spinal Muscular Atrophy Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

  • June 2017
  • 86 pages
  • ID: 5038654

Summary

Table of Contents

Disease Overview

Spinal muscular atrophy is a rare inherited genetic disease that is characterized by loss of nerve cells, known as motor neurons. Motor neurons receive the nerve impulses, which are transmitted from the brain to the spinal cord and, further transmits these impulses to the muscles with the help of peripheral nerves. The loss of motor neurons can lead to atrophy and weakness in the muscles, that are closest to the trunk of the body such as back, hips and shoulders. Spinal muscular atrophy is mainly caused due to the mutation in the SMA2 and SMN1 genes in chromosome. Any mutation in SMA1 gene can lead to spinal muscular atrophy.

According to National Organization for Rare Disorders, around 95% to 98% people who suffer from spinal muscular atrophy have deletions in the SMA1 (Survival of Motor Neuron 1) gene that results in a decreased production of SMN protein. The prevalence of spinal muscular atrophy has increased in the past few years, due to various risk factors such as smoking, family history, lack of awareness and delay in diagnosis. According to National Organization for Rare Disorders, the incidence of spinal muscular atrophy is approximately one in 10,000 live births. The disease is categorized into four types namely, Type I, Type II, Type III and Type IV. SMA Type I occurs mainly in infants aged between three to six months, with symptoms including very little muscle tone, weak muscles and feeding and breathing problems. SMA Type II and III both are very severe type of spinal muscular atrophy, and affects infants aged between six months to two years. SMA Type IV mainly affects the adult population. Some of the symptoms associated with spinal muscular atrophy include weakness in muscles, breathing difficulty, lack of head control, feeding difficulty and floppy infant (poor muscle tone).

Pipeline Analysis

As of June 2017, the spinal muscular atrophy pipeline comprises approximately 16 active drug candidates in different stages of development.

Spinal-Muscular-Atrophy-Therapeutics-Pipeline-Analysis

Competitive Landscape

Some of the other key players developing drugs for the treatment of spinal muscular atrophy include Cytokinetics, Inc., F. Hoffman La-Roche Ltd, WAVE Life Sciences Ltd. and others.

Scope for Customization

P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:

Market Forecast – Market analysis and forecast for the drug candidates in the latest stage of development
Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Alzheimer’s Disease Global Clinical Trials Review, H2, 2018

Alzheimer’s Disease Global Clinical Trials Review, H2, 2018

  • $ 2500
  • October 2018

Alzheimer’s Disease Global Clinical Trials Review, H2, 2018SummaryGlobalData’s clinical trial report, “Alzheimer’s Disease Global Clinical Trials Review, H2, 2018" provides an overview of Alzheimer’s ...

Wounds Global Clinical Trials Review, H2, 2018

Wounds Global Clinical Trials Review, H2, 2018

  • $ 2500
  • October 2018

Wounds Global Clinical Trials Review, H2, 2018SummaryGlobalData’s clinical trial report, “Wounds Global Clinical Trials Review, H2, 2018" provides an overview of Wounds clinical trials scenario.This ...

Allergies Global Clinical Trials Review, H2, 2018

Allergies Global Clinical Trials Review, H2, 2018

  • $ 2500
  • October 2018

Allergies Global Clinical Trials Review, H2, 2018SummaryGlobalData’s clinical trial report, “Allergies Global Clinical Trials Review, H2, 2018" provides an overview of Allergies clinical trials scenario.This ...


ref:plp2017

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on